(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh — Not every idea we bring to your attention as part of our Best Stocks in the Market list has a happy ending. In lots of cases, the trend we are analyzing simply reverses or fades away. Sometimes there is a change in a company’s fundamental outlook, sometimes there isn’t. Sometimes an analyst’s downgrade will wreck an uptrend and hand the joystick over to the bears. Sometimes a market-wide downturn will drag a Best Stock down into the depths with it. We have absolutely no control over these things, all we can control is how we’re going to respond — or not respond — when things change. This is why we always sign off with a strategy for risk management, usually in the form of a stop loss order or a level on the chart that should serve as a gut check where we ask ourselves, “Do we still want to be long here?” Getting out of the situations that don’t work out is essential to limit downside and keep ourselves liquid for new opportunities as more stocks are added to the list with fresher set-ups. And just as we want to cut our losers quickly, we want to ride the winners for as long as they remain Best Stocks in the Market. Today we’re going to look at some of these winners we’ve identified for you and give you a risk management update. Sean will relay some of these names, when we brought them to your attention and how things have been going since. I’ll chime in with some updated charts. Sean — Alnylam Pharmaceuticals (ALNY) , eBay (EBAY) and Carvana (CVNA) are our three best picks to date. We wrote up ALNY on 6/9/2025 with a total return of 49%, CVNA on 5/13/2025 returning 26%, and EBAY on 5/8/2025 returning 32%. All three have had different responses to the current macro environment, and all three are in slightly different trends. Before diving into the charts and headlines for each, let’s take a look at our normal Monday data drop: Sector Leaderboard As of Sept. 8, there are 201 names on The Best Stocks in the Market list Top Sector Ranking: Top Industries: Top 5 Best Stocks by Relative Strength: Risk Management – A key part of investing Josh — We pitched Alnylam Pharmaceuticals (ALNY) here on June 9th in an attempt to find a few strong names in the horrendously behaving healthcare sector. This one had broken out and we brought it to you then. Here we are a few months later and the stock has gained over 50% since our write-up. So far so good, as you can see above. I like this consolidation that’s taking place around the $450 level. I would remain long here if you caught it and use a sell-off that keeps the stock below $400 as a sign that something may have changed. But the longer it consolidates here with that RSI in the bottom pane moderating, the bigger the potential breakout once it gets going again. The company has a wave of catalysts coming into year-end and 2026, from insurance company reimbursement wins to treatment launches to clinical trials. How deep you want to go on something like this is a function of whether or not you’re a trader or an investor. Go to ALNY’s IR page here to keep track of it all . Sean — ALNY is making headlines with a mix of strong financial results, regulatory wins, and promising clinical data. In Q2 2025, the company delivered impressive earnings with total net product revenues of $672 million, up 64% year-over-year, fueled by a surge in franchise revenue led by AMVUTTRA, which brought in $544 million — a 77% increase. That strength prompted Alnylam to raise its full-year revenue guidance, now projecting up to $2.8 billion in product sales. On the regulatory front, the European Commission granted approval for AMVUTTRA to treat ATTR cardiomyopathy, marking the first RNAi therapeutic approved in Europe for this condition. The pipeline is also advancing, with zilebesiran, its hypertension candidate, set to enter a large Phase 3 outcomes trial (ZENITH) enrolling around 11,000 patients. Josh — We also showed you eBay (EBAY) on the verge of breaking out when it was just below $70 in early May. The stock has since run above $100 per share, another big winner that began to work out almost immediately and kept going. Below I’m showing you a year-to-date chart which has the most delicious low-volume pullback… Traders can pull the trigger and use the rising 50-day ($86) as a relatively tight stop. Look how flawlessly that 50-day has served as support all summer long — even when the de minimis loophole for tariff-free Chinese goods was closed and every ecommerce stock sold off on the news — the 50-day managed to hold. More patient investors in EBAY can watch for how it behaves should that early August gap get filled down to the $82-$82 area. If it’s orderly, I’d keep it. If it gets sloppy, I’d probably walk away. Sean — eBay is reinventing itself as it marks 30 years in business, investing heavily in AI to power personalized shopping, faster listings, and category leadership in trading cards, luxury goods, and refurbished items, which are all having a big moment right now. It has also expanded its Authenticity Guarantee to luxury clothing, offering expert vetting and QR-backed tracking to boost trust in secondhand goods. Financially, Q2 2025 was a standout quarter: revenue soared to $2.73 billion — a 6% increase year-over-year — while non-GAAP earnings per share rose 16% to $1.37, both beating expectations. Gross Merchandise Volume (GMV) also climbed to $19.5 billion, up 6% (4% FX-neutral), driven by strong growth in U.S. business and collectibles categories. Josh — Lastly, we brought you Carvana (CVNA) in a deep-dive piece we posted here on May 13th. The stock ran up a hundred points from the date we published for a gain of over 25% so far. As you can see below, CVNA’s gains have moderated but the uptrend is still very much intact. But the selling was orderly and a two-day breach of the 50-day moving average turned out to have been a false breakdown, quickly overcome by the bulls. I like the name here long so long as you understand the volatility you’re signing up for. CVNA has a beta coefficient of 3.5, making it more than three times more volatile than the overall stock market. Put another way, its monthly standard deviation is currently around 130% (annualized, five-year lookback). For comparison, the S & P 500’s is more like 15%. You want the heat, you gotta take the smoke. Sean — Carvana has delivered a remarkable turnaround, with Q2 2025 marking its strongest quarter ever—vehicle sales jumped 41% to 143,280 units, revenue rose 42% to $4.84 billion, and net income hit $308 million with a healthy 6.4% margin. Adjusted EBITDA climbed to $601 million (12.4% margin), prompting management to raise full-year guidance to as high as $2.2 billion. Analysts now highlight Carvana’s improved operations, customer-centric innovations like vending machines and home delivery, and strong profitability as key drivers of investor confidence. Josh — Let us know if this sort of update column is useful from time to time and we’ll try to bring back some of our previously written-up Best Stocks for you. DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC” TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.
